Olema Pharmaceuticals (OLMA)
Develops oral therapies for breast cancer and other endocrine-driven tumors.
Something off on this page? Send us feedback.
Develops targeted oncology drugs without marketed products, centered on palazestrant in late-stage breast cancer trials and OP-3136 in early clinical development. The business is organized as one consolidated segment and depends on clinical results, regulatory review, and future commercialization.
Builds a clinical-stage oncology pipeline around endocrine-driven cancers, especially ER+/HER2- metastatic breast cancer. Palazestrant is the wholly owned lead candidate, with pivotal monotherapy and ribociclib-combination studies. OP-3136 adds an earlier KAT6 inhibitor program for breast and other solid tumors.
Operations are centered in San Francisco with additional activity in Cambridge. The company has no approved commercial products or product-sales revenue, so current execution is clinical development, regulatory preparation, and potential launch planning rather than marketed portfolio management.
Business structure is simple: one consolidated reportable segment managed at the company level. Future value depends on trial readouts, FDA review, manufacturing readiness, and the ability to build a commercial oncology presence if palazestrant succeeds.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 14, 2026 | Stifel Nicolaus | Target | Target: $48 | Target: $30 |
| Aug 11, 2026 | Goldman Sachs | Target | Target: $38 | Target: $20 |
| May 13, 2026 | Guggenheim | Reiterate | Rating: —Target: $40 | Target: $35 |
| Mar 9, 2026 | H.C. Wainwright | Target | Target: $45 | Target: $38 |
| Feb 10, 2026 | Stifel Nicolaus | Target | Target: — | Target: $48 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $461.1M · Total debt $660.0K · Total assets $486.6M · Shareholders' equity $430.6M
- Revenue
- $0
- Operating income
- −$67.2M
- Net income
- −$63.2M
No dividends on record.
| Institutions | 117.08% | 102.44M shares | |
|---|---|---|---|
| 201 holders · as of Jun 30, 2026 | |||
| Insiders | 2.18% | 1.91M shares | |
| 7 holders · as of Jul 27, 2026 | |||
| Strategic holders | 8.52% | 7.46M shares | |
| 2 holders · as of May 15, 2026 | |||
| Adds to | 127.78% | ||
87.50M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.78%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 13.88% | 12.14M | as of Jun 30, 2026 |
Paradigm Biocapital Advisors LPInstitution | 9.91% | 8.67M | as of Jun 30, 2026 |
Bain Capital Life Sciences Opportunities IV, L.P.Institution | 8.54% | 7.47M | filed May 15, 2026 |
Janus Henderson Group PLCStrategic | 8.12% | 7.11M | filed May 15, 2026 |
Jupiter Topco LLCInstitution | 8.11% | 7.09M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmon | director | −12,500 | $11.71 |
| Jul 23, 2026 | Cyrus Harmon | director | −12,500 | $11.58 |
| Mar 3, 2026 | Shawnte Mitchell | officer: CHIEF LEGAL OFFICER | −15,000 | $23.01 |
| Mar 4, 2026 | Shawnte Mitchell | officer: CHIEF LEGAL OFFICER | −25,000 | $24.25 |
| Jan 20, 2026 | Cyrus Harmon | director | −10,000 | $26.88 |
- AstraZeneca (ADR)
Direct ER breast-cancer rival through Faslodex and camizestrant
- Eli Lilly
Approved oral ER antagonist in the same metastatic breast-cancer lane
- Arvinas
Phase 3 ER degrader peer with vepdegestrant
- Pfizer
Partnered ER degrader and KAT6 programs overlap both pipeline pillars
- LeonaBio
Phase 3 lasofoxifene challenger in ESR1-mutated metastatic disease
- BeOne Medicines (ADR)
KAT6A/B inhibitor peer for OP-3136
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Olema Pharmaceuticals | $9.73 | +0.99% | $841.2M | — | — | — | — |
| AstraZeneca (ADR) | $168.47 | +0.22% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Eli Lilly | $1,169.22 | +0.37% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Arvinas | $8.44 | +1.73% | $535.5M | 51.9 | — | 1.7 | +1,014.7% |
| Pfizer | $27.83 | +0.31% | $158.10B | 36.7 | 9.9 | 2.5 | +2.6% |
| LeonaBio | $6.24 | −1.50% | $25.0M | — | — | — | — |
| BeOne Medicines (ADR) | $363.62 | −0.56% | $39.07B | 5.1 | 46.1 | 6.4 | +29.6% |
| Median | 36.7 | 22.2 | 4.2 | +29.6% |